Severe adverse events are in general rare. Skin and subcutaneous disorders are the most frequently reported, but these generally resolve after drug cessation.<unk>  shows less adverse effects of anterograde amnesia, sedation, impaired psychomotor performance, and withdrawal syndromes than those of benzodiazepines. A 2012 review of<unk>  by the French National Pharmacovigilance Committee determined that<unk>  was safe and continued to provide a favorable alternative to benzodiazepine anxiolytics. The committee found (for a ten-year pharmacovigilance period) that safety concerns were rare or very rare and that the incidence of idiosyncratic hepatic problems were very rare.
Etifoxine
Quinine
Ipriflavone
Tuberculinic acid
Trenbolone hexahydrobenzylcarbonate
Artemether
Milbemycin oxime
Dimetacrine